Genocea Biosciences have announced the publication of preclinical trial results for their investigational therapeutic HSV-2 vaccine. The results, published in Journal of Virology, show that vaccination with GEN-003 and Isconova AB's Matrix-M adjuvant was capable of inducing antigen- and virus-specific immune responses. The vaccine improved outcomes in preclinical models of HSV-2 disease. GEN-003 showed a significant impact on viral shedding after completion of the dosing regimen.
GEN-003 is a therapeutic T cell vaccine that Genocea say is designed to reduce the duration, severity and transmission of moderate-to-severe genital herpes infection. GEN-003 is different to previous HSV-2 vaccine candidates because it is designed to mount a balance of both T cell and B cell responses.
“These results provide strong support for our ongoing clinical investigation of GEN-003, and provide further validation of our approach for identifying promising, next-generation vaccine candidates capable of preventing and treating a wide variety of complex pathogens,” said Chip Clark, CEO of Genocea.
Genocea has now fully enrolled a Phase 1/2a study of GEN-003, and hopes to be reporting on preliminary data in the latter half of 2013.
Are you excited by the results? Do you think GEN-003 could solve an important issue?
You can join our discussion on LinkedIn or leave a comment below, I'd love to hear what you think.
If you'd like to know more about strategy and innovation in vaccines, you might like to consider attending the World Vaccine Congress and Expo 2013 on the 16-18 April 2013, Gaylord National Hotel and Convention Center, Washington DC. You can download the brochure here.